Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 0.94 |
| ▸ | LMNA | P02545 | 1/20 | 0.94 |
| ▸ | MAPT | P10636 | 1/20 | 0.94 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.94 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.94 |
| ▸ | ANPEP | P15144 | 7/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.50 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | LAP3 | P28838 | 3/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15980655 | 0.82 | — | — | |
| SCHEMBL56311 | 0.77 | ANPEP (0.65) | TSHRCYP3A4CYP2D6NFKB1THPO | |
| SCHEMBL9767481 | 0.76 | TSHR (0.61) | TSHRCYP3A4CYP2D6NFKB1THPO | |
| SCHEMBL9767473 | 0.76 | TSHR (0.61) | TSHRCYP3A4CYP2D6NFKB1THPO | |
| Hydrochloric Acid SCHEMBL56763 | 0.74 | GMNN (0.63) | TSHRCYP3A4CYP2D6NFKB1THPO | |
| SCHEMBL10343746 | 0.74 | ANPEP (0.61) | TSHRCYP3A4CYP2D6NFKB1THPO | |
| SCHEMBL27395315 | 0.73 | — | — | |
| SCHEMBL28769846 | 0.73 | — | — | |
| SCHEMBL859533 | 0.71 | TSHR (0.54) | TSHRCYP3A4CYP2D6NFKB1THPO | |
| SCHEMBL19067097 | 0.69 | CYP3A4 (0.52) | TSHRCYP3A4CYP2D6NFKB1THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181206-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140194426-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8598170-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2456762-B1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE INC (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20130196997-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-08-01 | — | — | US | disclosed |
| US-8372984-B2 | Dual-acting oxazole antihypertensive agents | THERAVANCE, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20110021527-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021527-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | TSHR 276/4885CYP3A4 1539/4885CYP2D6 987/4885 |
| US-20130196997-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | TSHR 276/4885CYP3A4 1539/4885CYP2D6 987/4885 |
| US-20140194426-A1 | DUAL-ACTING OXAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | TSHR 276/4885CYP3A4 1539/4885CYP2D6 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.